Yale's Colton Center for Autoimmunity has selected nine researchers for nearly $1 million in 2025 funding, backing projects that apply AI, nanoparticles, and novel biologics to autoimmune disease.
Yale's Colton Center for Autoimmunity has selected eleven faculty-led projects for 2024 funding, supporting breakthrough research into lupus, asthma, allergies, and other autoimmune diseases — with mentorship and commercialization support included.
Tel Aviv University's Colton Center has awarded nine interdisciplinary research grants in 2024, funding projects that explore autoimmune disease from organ-on-a-chip platforms to the role of stress and psychological factors in disease flare-ups.
NYU Langone researchers have linked lupus flare-ups to blooms of a specific gut bacterium, opening a potential path to probiotic and dietary treatments less toxic than current immunosuppressive therapies.
Tel Aviv University's Colton Center for Autoimmunity joins a four-university consortium dedicated to finding cures for over 100 autoimmune diseases through big data analytics, multidisciplinary research, and international collaboration.
NYU Langone's Colton-backed Division of Rheumatology is taking a leading role in the NIH's $58 million AMP AIM program, driving research into lupus, psoriatic disease, Sjögren's disease, and the microbiome.
Yale Medicine Magazine profiles Colton-funded researchers using skin as a diagnostic and therapeutic entry point into autoimmune disease — from scleroderma antibody therapy to cancer-triggered bullous pemphigoid.
Colton-supported NYU researchers have found that autoantibodies can physically inactivate a key enzyme in over half of lupus nephritis patients — a non-genetic mechanism that could serve as a future biomarker and therapeutic target.
NYU Langone's Colton Center has funded seven new autoimmune pilot projects for 2019 — targeting myasthenia gravis, rheumatoid arthritis, and lupus — while earlier grants advance toward clinical diagnostics and therapies.
